Date published: 2026-3-31

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr1235 Inhibitors

Olr1235 inhibitors are a specialized class of chemical compounds that are specifically designed to interact with and inhibit the function of the Olr1235 receptor, a member of the olfactory receptor family within the G protein-coupled receptor (GPCR) superfamily. Olr1235 receptors play a critical role in the olfactory system, which is responsible for the detection and interpretation of odorant molecules, ultimately contributing to the sense of smell. These inhibitors function by binding to the receptor's active site or other regulatory regions, thereby blocking the receptor's ability to interact with its natural ligands. This interaction prevents the receptor from undergoing the conformational changes necessary for the activation of intracellular signaling pathways that typically follow ligand binding. The design of Olr1235 inhibitors often involves detailed structural studies of the receptor, utilizing techniques such as X-ray crystallography, molecular dynamics simulations, and cryo-electron microscopy. These studies provide crucial insights into the receptor's binding pockets and other important features, allowing for the creation of inhibitors that are highly specific to the Olr1235 receptor.

Chemically, Olr1235 inhibitors exhibit a diverse range of structures and properties, reflecting the various approaches used in their synthesis and development. These compounds may be small, hydrophobic molecules capable of easily crossing cellular membranes to reach their target receptors, or they may be larger, more complex molecules that require sophisticated synthetic techniques to achieve the desired binding affinity and selectivity. The synthetic pathways used to create Olr1235 inhibitors often involve multiple steps of organic synthesis, including the formation of key functional groups that are critical for binding to the receptor. After synthesis, these compounds undergo rigorous characterization using analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and high-performance liquid chromatography (HPLC) to confirm their structural integrity, purity, and inhibitory activity. The study of Olr1235 inhibitors not only advances our understanding of the specific mechanisms by which this olfactory receptor operates but also contributes to a broader knowledge of GPCR modulation. This research provides valuable insights into how these complex receptors can be selectively targeted and regulated by small molecules, which is essential for deepening our understanding of the molecular processes involved in sensory perception, particularly in the context of olfaction.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$75.00
$121.00
33
(1)

EGFR inhibitor, potentially interrupts cell signaling and proliferation in certain cancers.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Raf kinase inhibitor, potentially disrupts cell signaling in various malignancies.

Lenvatinib

417716-92-8sc-488530
sc-488530A
sc-488530B
5 mg
25 mg
100 mg
$182.00
$661.00
$1690.00
3
(0)

Multi-kinase inhibitor, might affect VEGFR, FGFR, PDGFR, RET, and KIT pathways.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$114.00
$166.00
$947.00
19
(1)

MEK inhibitor, potentially modulates cell signaling in melanoma and other cancers.

Afatinib

439081-18-2sc-364398
sc-364398A
5 mg
10 mg
$114.00
$198.00
13
(2)

Targets EGFR, HER2, and HER4, potentially interrupting proliferative signaling pathways.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Dual EGFR and HER2 inhibitor, could hinder cell growth in breast cancer.

Osimertinib

1421373-65-0sc-507355
5 mg
$86.00
(0)

EGFR inhibitor, may affect non-small cell lung cancer with specific mutations.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

EGFR tyrosine kinase inhibitor, potentially blocks signaling in lung cancer.

Dabrafenib

1195765-45-7sc-364477
sc-364477A
sc-364477B
sc-364477C
sc-364477D
5 mg
25 mg
50 mg
100 mg
10 g
$141.00
$260.00
$278.00
$411.00
$12485.00
6
(1)

BRAF inhibitor, might affect melanoma cells with BRAF mutations.

Ribociclib

1211441-98-3sc-507367
10 mg
$450.00
(0)

CDK4/6 inhibitor, potentially delays cell cycle progression in hormone receptor-positive breast cancer.